BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LDR Announces FDA Clearance of the ROI-A(R) Oblique ALIF Cage


11/1/2011 6:50:17 AM

AUSTIN, Texas--(BUSINESS WIRE)-- LDR, a privately held medical device company offering innovative spinal implants for both non-fusion and fusion applications, announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the ROI-A Oblique ALIF cage. The oblique cage complements its forerunner, the ROI-A ALIF cage, which is designed for direct anterior insertion. When used with the company’s integrated VerteBRIDGE plating technology, both devices address the growing interest in the market for stand-alone lumbar fusion technology that reduces the need for additional anterior or posterior instrumentation. In addition to providing the benefits of ALIF surgery, a key feature of the ROI-A Oblique system is the opportunity to minimize the mobilization of the anterior vessels, without requiring the surgeon to consider a trans-psoatic lateral approach that may present increased neurologic risks and necessitate neuromonitoring.

Christophe Lavigne, President and CEO of LDR, comments, “We are excited to strengthen our worldwide leadership in stand-alone device innovation by introducing the first oblique ALIF stand-alone cage into the U.S. market. This follows on the heels of our recent approval in China to market both the ROI-A ALIF and ROI-C® Cervical cages. The ROI-A Oblique represents the latest application of VerteBRIDGE plating technology, which has been successfully used in more than 17,000 cage implantations worldwide since 2008, with September 2011 marking the first month in which over 1,000 cages using VerteBRIDGE plating were implanted.”

Dr. Federico P. Girardi, Associate Attending Orthopaedic Surgeon at the Hospital for Special Surgery and Associate Professor of Orthopaedics at Weill Cornell Medical College in New York, implanted the first ROI-A Oblique ALIF cage in the U.S. and shares the company’s enthusiasm about the product. “A critical aspect of ALIF surgery is gaining access to the disc, especially at the L4-L5 level, where there may be significant concerns about management of the anterior vessels through a direct anterior approach and navigating the nerves within the psoas through a direct lateral approach. LDR has acknowledged and addressed these challenges with an innovative addition to its product line. The ROI-A Oblique ALIF cage serves a previously unmet need in lumbar surgery, and allows me to deliver better care to my patients.”

The oblique cage and self-guided, curved VerteBRIDGE plating are delivered in the plane of the disc through a direct anterolateral approach so that the implantation may be achieved with less exposure than may be required to place a traditional ALIF cage or even contemporary stand-alone systems with screws that must be inserted at divergent angles. The system features thoughtfully designed instrumentation including an inserter that protects anatomical structures while implanting the cage and plating. Clinical evaluation of the ROI-A Oblique cage began in France in 2009 with over 150 cases completed prior to its market introduction in the United States.

LDR was founded in 2000 by partners Christophe Lavigne, Hervé Dinville and Patrick Richard in Troyes, France. Currently headquartered in Austin, TX, LDR has experienced rapid growth through product portfolio expansion and an increasingly global presence. LDR develops unique implantable spine devices and instrumentation designed to support the clinical goals of surgery while making procedures easier to perform. More information is located at www.ldrholding.com.

©2011 LDR Holding Corporation, All Rights Reserved

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50049017&lang=en

MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50049017&lang=en

Contact:

LDRJoe Ross, 512-344-3410Vice President of U.S. Marketingjoeross@ldrspine.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES